Most Read Articles
Rachel Soon, 24 Apr 2018

MIMS Pharmacist presents an overview of CoQ10's physiological role, as well as contemporary research on its pharmacology and effects.

Roshini Claire Anthony, 22 Apr 2020

Patients with cancer who develop venous thromboembolism (VTE) could reduce their risk of VTE recurrence with the direct oral anticoagulant (DOAC) apixaban, which demonstrated noninferiority to subcutaneous dalteparin in the Caravaggio* trial.

Jairia Dela Cruz, 25 Jun 2020
Scientists are looking to the possibility of repurposing a common heartburn remedy, famotidine, to combat COVID-19, with a small case series study showing that the use of the drug is safe and leads to symptomatic improvements in infected patients.

Standard ART plus maraviroc does not improve outcomes in treatment-naïve HIV patients

18 Mar 2020

Adding maraviroc to standard combined antiretroviral therapy (c-ART), which consists of three or more ART drugs, does not result in better clinical outcomes among patients initiating treatment for advanced HIV infection, reveals a study.

A total of 409 HIV-positive, antiretroviral-naïve adults with CD4 counts <0.200 × 109 cells/L and/or a previous AIDS-defining event (ADE) were enrolled in this randomized controlled trial to assess the benefit of adding maraviroc to standard c-ART.

Of the participants, 202 were assigned to maraviroc and 207 to placebo. Participants received c-ART plus placebo or maraviroc (300 mg twice daily with dose modification) for 72 weeks.

During follow-up, the primary endpoint of first occurrence of severe morbidity (ie, new ADE, selected serious infections, serious non-ADE, immune reconstitution inflammatory syndrome or death) was comparable between the two treatment groups (11.1 vs 11.2 person-years in the maraviroc and placebo groups, respectively; hazard ratio, 0.97, 95 percent confidence interval [CI], 0.57–1.67).

In addition, the incidence of adverse events grade 2 was 36.1 vs 41.5 per 100 person-years (incidence rate ratio, 0.87, 95 percent CI, 0.65–1.15), respectively.

Certain limitations have to considered. First, 64 patients discontinued treatment during follow-up. Second, the study was not powered to assess time-dependent outcomes or effect modification.

“Patients diagnosed with advanced HIV infection have a poor prognosis despite initiation of c-ART,” the investigators said.

Maraviroc is an ART with immunologic effects, they noted.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Rachel Soon, 24 Apr 2018

MIMS Pharmacist presents an overview of CoQ10's physiological role, as well as contemporary research on its pharmacology and effects.

Roshini Claire Anthony, 22 Apr 2020

Patients with cancer who develop venous thromboembolism (VTE) could reduce their risk of VTE recurrence with the direct oral anticoagulant (DOAC) apixaban, which demonstrated noninferiority to subcutaneous dalteparin in the Caravaggio* trial.

Jairia Dela Cruz, 25 Jun 2020
Scientists are looking to the possibility of repurposing a common heartburn remedy, famotidine, to combat COVID-19, with a small case series study showing that the use of the drug is safe and leads to symptomatic improvements in infected patients.